NASDAQ · TYRA
Healthcare · Biotechnology
$25.43
Down-$1.08 (-4.25%)
Updated Sep 17, 2026, 12:05 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
TYRA closed at $25.43 after 19 trading sessions, down 5.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $24.71 | $25.775 | $24.15 | $25.43 | 1.14M |
| Sep 14, 2026 | $23.20 | $26.36 | $23.20 | $25.07 | 2.07M |
| Sep 11, 2026 | $23.63 | $23.96 | $21.86 | $22.03 | 1.55M |
| Sep 10, 2026 | $21.41 | $23.64 | $21.2744 | $23.54 | 2.48M |
| Sep 9, 2026 | $18.94 | $22.3018 | $18.66 | $22.01 | 6.07M |
| Sep 8, 2026 | $27.95 | $29.49 | $26.70 | $26.73 | 1.16M |
| Sep 4, 2026 | $24.51 | $29.56 | $24.51 | $28.65 | 1.86M |
| Sep 3, 2026 | $25.22 | $25.585 | $24.61 | $24.86 | 603.55K |
| Sep 2, 2026 | $25.52 | $26.42 | $24.80 | $25.13 | 567.92K |
| Sep 1, 2026 | $24.99 | $25.59 | $24.84 | $25.30 | 423.51K |
| Aug 31, 2026 | $24.82 | $25.21 | $24.17 | $25.03 | 423.8K |
| Aug 28, 2026 | $25.88 | $25.88 | $24.91 | $24.94 | 217.5K |
| Aug 27, 2026 | $26.17 | $26.685 | $25.92 | $26.13 | 253.99K |
| Aug 26, 2026 | $26.63 | $26.79 | $26.03 | $26.22 | 286.93K |
| Aug 25, 2026 | $26.47 | $26.99 | $26.30 | $26.69 | 317.81K |
| Aug 24, 2026 | $25.99 | $26.42 | $25.18 | $26.09 | 321.12K |
| Aug 21, 2026 | $25.95 | $26.81 | $25.95 | $26.05 | 493.6K |
| Aug 20, 2026 | $26.36 | $26.36 | $25.0825 | $25.69 | 324.48K |
| Aug 19, 2026 | $26.69 | $26.98 | $26.27 | $26.81 | 303.63K |
The latest Smart Investors Daily articles mentioning TYRA.
TYRA research
Company profile and research snapshot.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | Wedbush | Outperform | — |
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 4, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 17, 2026 | Jones Trading | Buy | — |
| Jun 10, 2026 | B of A Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 15, 2026
U.S. stock futures declined on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Monday's lower close.
Benzinga · Sep 14, 2026
U.S. stocks fell Monday as tech slid; Nvidia may invest $10B in Anthropic’s IPO. Oil rose 3%, while gold, silver and copper declined.
Yahoo · Sep 14, 2026
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22
Benzinga · Sep 14, 2026
Underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TYRA.
